Category: COVID-19 Developments

16 posts found

WCRI Publishes Long COVID Report

The likelihood of long COVID, claims costs, and claim duration all increased with the severity of acute COVID-19.

The only pre-exposure prophylactic for COVID-19 may not provide protection for certain variants.

Moderna and Pfizer boosters have been updated to target the omicron variant.

Adults aged 50 and older and immunocompromised individuals may receive a second booster dose.

Drug advancements surrounding the prevention and treatment of COVID-19.

Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.

All adults may now receive a booster shot of any COVID-19 vaccine.

All COVID-19 vaccines now have emergency use authorization for a booster dose.

Another WCRI report looks at non-COVID-19 claims with injuries in the first two quarters of 2019 and 2020.

Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.

The single-dose Janssen vaccine was analyzed in a trial of 39,000 patients.

Data from nearly 12,000 COVID-19 claims breaks down coverage among industries, telemedicine insights, and more.

With cases increasing as individuals return to work, injured workers face barriers to care, risk of infection, and more.

The National Safety Council discusses managing employee anxiety stemming from COVID-19 when returning to work.

A new study explores patients’ use of health services, the impact on medicine use, research activity, and more.

1 2 Next